Jeffrey M Burns1, David K Johnson2, Edward P Liebmann3, Rebecca J Bothwell4, Jill K Morris4, Eric D Vidoni4. 1. Department of Neurology, University of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: jburns2@kumc.edu. 2. Department of Neurology, University of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, KS, USA; Department of Psychology, University of Kansas, Lawrence, KS, USA. 3. Department of Psychology, University of Kansas, Lawrence, KS, USA. 4. Department of Neurology, University of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, KS, USA.
Abstract
INTRODUCTION: Disclosing amyloid status to cognitively normal individuals remains controversial given our lack of understanding the test's clinical significance and unknown psychological risk. METHODS: We assessed the effect of amyloid status disclosure on anxiety and depression before disclosure, at disclosure, and 6 weeks and 6 months postdisclosure and test-related distress after disclosure. RESULTS: Clinicians disclosed amyloid status to 97 cognitively normal older adults (27 had elevated cerebral amyloid). There was no difference in depressive symptoms across groups over time. There was a significant group by time interaction in anxiety, although post hoc analyses revealed no group differences at any time point, suggesting a minimal nonsustained increase in anxiety symptoms immediately postdisclosure in the elevated group. Slight but measureable increases in test-related distress were present after disclosure and were related to greater baseline levels of anxiety and depression. DISCUSSION: Disclosing amyloid imaging results to cognitively normal adults in the clinical research setting with pre- and postdisclosure counseling has a low risk of psychological harm.
INTRODUCTION: Disclosing amyloid status to cognitively normal individuals remains controversial given our lack of understanding the test's clinical significance and unknown psychological risk. METHODS: We assessed the effect of amyloid status disclosure on anxiety and depression before disclosure, at disclosure, and 6 weeks and 6 months postdisclosure and test-related distress after disclosure. RESULTS: Clinicians disclosed amyloid status to 97 cognitively normal older adults (27 had elevated cerebral amyloid). There was no difference in depressive symptoms across groups over time. There was a significant group by time interaction in anxiety, although post hoc analyses revealed no group differences at any time point, suggesting a minimal nonsustained increase in anxiety symptoms immediately postdisclosure in the elevated group. Slight but measureable increases in test-related distress were present after disclosure and were related to greater baseline levels of anxiety and depression. DISCUSSION: Disclosing amyloid imaging results to cognitively normal adults in the clinical research setting with pre- and postdisclosure counseling has a low risk of psychological harm.
Authors: Adam S Fleisher; Kewei Chen; Xiaofen Liu; Auttawut Roontiva; Pradeep Thiyyagura; Napatkamon Ayutyanont; Abhinay D Joshi; Christopher M Clark; Mark A Mintun; Michael J Pontecorvo; P Murali Doraiswamy; Keith A Johnson; Daniel M Skovronsky; Eric M Reiman Journal: Arch Neurol Date: 2011-07-11
Authors: Richard J Caselli; Gary E Marchant; Katherine S Hunt; Bruce R Henslin; Heidi E Kosiorek; Jessica Langbaum; Jason S Robert; Amylou C Dueck Journal: Alzheimer Dis Assoc Disord Date: 2015 Jul-Sep Impact factor: 2.703
Authors: Robert C Green; J Scott Roberts; L Adrienne Cupples; Norman R Relkin; Peter J Whitehouse; Tamsen Brown; Susan LaRusse Eckert; Melissa Butson; A Dessa Sadovnick; Kimberly A Quaid; Clara Chen; Robert Cook-Deegan; Lindsay A Farrer Journal: N Engl J Med Date: 2009-07-16 Impact factor: 91.245
Authors: Howard Jay Aizenstein; Robert D Nebes; Judith A Saxton; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Scott K Ziolko; Jeffrey A James; Beth E Snitz; Patricia R Houck; Wenzhu Bi; Ann D Cohen; Brian J Lopresti; Steven T DeKosky; Edythe M Halligan; William E Klunk Journal: Arch Neurol Date: 2008-11
Authors: Hilary A Archer; Paul Edison; David J Brooks; Jo Barnes; Chris Frost; Tom Yeatman; Nick C Fox; Martin N Rossor Journal: Ann Neurol Date: 2006-07 Impact factor: 10.422
Authors: S A S A Bemelmans; K Tromp; E M Bunnik; R J Milne; S Badger; C Brayne; M H Schermer; E Richard Journal: Alzheimers Res Ther Date: 2016-11-10 Impact factor: 6.982
Authors: Arno de Wilde; Wiesje M van der Flier; Wiesje Pelkmans; Femke Bouwman; Jurre Verwer; Colin Groot; Marieke M van Buchem; Marissa Zwan; Rik Ossenkoppele; Maqsood Yaqub; Marleen Kunneman; Ellen M A Smets; Frederik Barkhof; Adriaan A Lammertsma; Andrew Stephens; Erik van Lier; Geert Jan Biessels; Bart N van Berckel; Philip Scheltens Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Andrew J Aschenbrenner; Bryan D James; Eric McDade; Guoqiao Wang; Yen Ying Lim; Tammie L S Benzinger; Carlos Cruchaga; Alison Goate; Chengjie Xiong; Richard Perrin; Virginia Buckles; Ricardo Allegri; Sarah B Berman; Jasmeer P Chhatwal; Anne Fagan; Martin Farlow; Antoinette O'Connor; Bernardino Ghetti; Neill Graff-Radford; Jill Goldman; Susanne Gräber; Celeste M Karch; Jae-Hong Lee; Johannes Levin; Ralph N Martins; Colin Masters; Hiroshi Mori; James Noble; Stephen Salloway; Peter Schofield; John C Morris; Randall J Bateman; Jason Hassenstab Journal: Alzheimers Dement Date: 2020-01 Impact factor: 21.566
Authors: Melissa J Armstrong; Gary S Gronseth; Gregory S Day; Carol Rheaume; Slande Alliance; C D Mullins Journal: Alzheimer Dis Assoc Disord Date: 2019 Jul-Sep Impact factor: 2.703
Authors: Matthew K Taylor; Debra K Sullivan; Russell H Swerdlow; Eric D Vidoni; Jill K Morris; Jonathan D Mahnken; Jeffrey M Burns Journal: Am J Clin Nutr Date: 2017-10-25 Impact factor: 7.045
Authors: Carolyn S Kaufman; Robyn A Honea; Joseph Pleen; Rebecca J Lepping; Amber Watts; Jill K Morris; Sandra A Billinger; Jeffrey M Burns; Eric D Vidoni Journal: J Cereb Blood Flow Metab Date: 2021-01-28 Impact factor: 6.200
Authors: Emily A Largent; Maramawit Abera; Kristin Harkins; Sara J Feldman; Wendy R Uhlmann; J Scott Roberts; Jason Karlawish Journal: J Am Geriatr Soc Date: 2021-07-12 Impact factor: 5.562